electrophysiology News
-
Acutus Medical to Present at the 21st Annual Needham Virtual Healthcare Conference
Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:45 p.m. Eastern Time. A live webcast of the presentation may be accessed by visiting ...
-
Modern electroretinography from the manufacturer with longest legacy at the market.
LKC Technologies Inc. is proud to announce that the OCULUS Instruments Ltd, will continue to support existing and new customers of the RETeval® device and UTAS™ systems in the territory of United Kingdom and Ireland. Brian Moran and Pamela Ferguson have been working with LKC products for many years, are looking forward to receiving any requests from you. The LKC Technologies products ...
-
Zhejiang Medical Association Cardiac Electrophysiology
The 2019 Zhejiang Electrocardiogram and Pacing Academic Annual Meeting was held from June 27th to June 30th at the Great Hall of the People in Hangzhou, Zhejiang Province. Our company is honored to provide full technical support for the ECG big contest. ...
-
FARAPULSE Receives European Approval To Commercialize Its Leading Pulsed Field Ablation System To Treat Paroxysmal Atrial Fibrillation
FARAPULSE Inc. ("FARAPULSE" or "the Company") today announced that it has received the Conformite Europeene (CE) Mark for its FARAPULSE Pulsed Field Ablation (PFA) system for the treatment of Paroxysmal Atrial Fibrillation (AF). The approval makes FARAPULSE the first company in the world to commercialize a cardiac PFA system and permits marketing of the system across the European Union and other ...
-
Liposomal Bupivacaine (Bupigel) Demonstrates Minimal Local Nerve Toxicity in a Rabbit Functional Model
Abstract: We previously reported the development of a novel formulation of an ultra-long-acting local anesthetic based on bupivacaine encapsulated in large multivesicular liposomes (Bupisomes) embedded in hydrogel. This formulation (Bupigel) prolonged bupivacaine release from the formulation in dissolution-like studies in vitro and analgesia in vivo in mouse, rat, and pig models. In this study we ...
-
Vektor Medical Initiates Clinical Study of vMap
Vektor Medical, Inc. announced the start of its clinical study to evaluate vMap™. Using patients who have previously undergone a clinically-indicated electrophysiology study and successful ablation, the purpose of this study is to clinically validate the use of vMap™ in providing arrhythmia/pacing hotspots for analysis by a physician. vMap™ has been designed as the next ...
-
$30 Million Series B Financing and Expansion of Scientific Advisory Board
Ablacon, Inc., an Ajax Health-backed company, announced the close of a $30 million Series B financing, with Zeus Health joining as new lead investor. Ablacon also announced the addition of Dr. David Haines, Professor of Cardiovascular Medicine at Oakland University William Beaumont School of Medicine and Director of the Heart Rhythm Center at Beaumont Health, Royal Oak, MI, to the ...
-
Acutus Medical completes enrollment in IDE trial with its AcQBlate FORCE Sensing Ablation System
Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced successful completion of patient enrollment in the company’s AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally. The AcQForce Flutter trial was designed to ...
-
AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for long-standing persistent Afib patients. Study also showed improved Electrophysiology Lab efficiency AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced U.S. Food and ...
-
Newly Published Studies Show Motor Recovery in Chronic Stroke Patients
Neurolutions CSO and Founder Dr. Eric Leuthardt has contributed to two recently published studies showing proof that brain-computer interface therapy with the IpsiHand benefits the brain's motor networks and also motor recovery in chronic stroke patients with extended usage. Brain-Computer Interface – The Future of Rehabilitation Brain-computer interface rehabilitation using the IpsiHand ...
By Neurolutions
-
Galaxy Medical ECLIPSE-AF Study to be Featured in Innovative Technology Session at EHRA 2021 Annual Scientific Meeting
SAN CARLOS, California, April 22, 2021 — Galaxy Medical announced today that the acute results of its Europe-focused ECLIPSE-AF study will be featured during the upcoming EHRA Congress in a innovative Technology presentation on April 25th by Ante Ani , M.D., Electrophysiology Laboratory Director at University Clinical Hospital in Split, Croatia, and primary investigator of the study. The ...
-
Cardiva Medical Announces First Patients Enrolled in The AMBULATE Same Day Discharge Study Using VASCADE MVP
SANTA CLARA, Calif., July 16, 2020 -- Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the first patient enrollments in its AMBULATE Same Day Discharge study, the first prospective multi-center study designed to evaluate same-day discharge for patients undergoing cardiac ablation procedures for atrial fibrillation. The study is utilizing the VASCADE MVP Venous ...
-
LKC Technologies Announces Brazilian Health Regulatory Agency Approval for the UTAS™ System
LKC Technologies is pleased to announce that the Brazilian Health Regulatory Agency (Anvisa) has granted approval of the UTAS® device, making this a significant advancement in the preservation and enhancement of sight for patients in Brazil. LKC is collaborating with Oculus Brasil to provide physicians with broader access to LKC’s UTAS System and RETeval devices. Both are in extensive ...
-
Kardium® announces successful results from the GLOBAL-AF study
VANCOUVER, British Columbia — Kardium Inc. today announced that the Globe® Mapping and Ablation System has successfully demonstrated safety and efficacy in the GLOBAL-AF study. The results of the study were published in the Journal of Cardiovascular Electrophysiology. The study demonstrated a 76% percent freedom from atrial fibrillation at 12 months after a single treatment with the ...
By Kardium Inc.
-
CoreMap Wins National Science Foundation Phase 1 SBIR Award
CoreMap, Inc. announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF) to support development of its technology aimed at expanding treatment opportunities for patients with Atrial Fibrillation (AF). AF is the most common and complex cardiac arrythmia affecting 33 million patients globally where patients are at ...
By CoreMap Inc.
-
Kardium receives CE mark for Globe® Mapping and Ablation System
VANCOUVER, British Columbia – Kardium Inc. has received CE mark approval for its Globe Mapping and Ablation System – the most complete solution for the treatment of atrial fibrillation (AF). AF is the world’s most common heart rhythm disorder, affecting more than 37 million people. This approval allows Kardium to begin commercial sales of the Globe System in Europe. “This ...
By Kardium Inc.
-
Galaxy Medical Releases ECLIPSE-AF Remapping Data at Stanford Biodesign Retreat and Update on System Interoperability
SAN CARLOS, California, July 28, 2021 — Galaxy Medical announced today that the ECLIPSE-AF 90-day remapping data, presented at the Stanford BioDesign New Arrhythmia Technologies retreat, demonstrated durable lesions and chronic pulmonary vein isolation (PVI). Also, the company has recently treated patients in the same study using CE-Marked catheters and mapping systems from Boston ...
-
Inscopix Launches Cloud-Based Platform for Data Management and Analysis to Advance Neurotherapeutic Development
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched IDEAS, a cloud-based platform for enterprisesthat supports the integration, organization, management and sharing of neuroscience research, data and methods to accelerate development of the next-generation of neurotherapeutics. Today, neuroscience groups frequently use ...
-
Ablacon Announces Closing of a $10 Million Venture Debt Facility and $2 Million Equity Investment from Western Technology Investment; Josef Koblish and Melissa Kong to Join the Company
Ablacon Inc. announced today that it has entered into a $10 million venture debt facility with Western Technology Investment (WTI). The debt is accompanied by a $2 million equity investment in the Company. This financing will help fund Ablacon's first multicenter randomized clinical trial for Ablamap, an advanced mapping system for patients with atrial fibrillation. "WTI has been a trusted ...
-
Cardiva Medical Announces FDA Approval of the VASCADE MVP Vascular Closure System for Multi-Site Vessel Closure Following Electrophysiology Procedures
VASCADE MVP is the first vessel closure technology designed for electrophysiology procedures – and proven by electrophysiology physicians in a multi-center, randomized, controlled clinical trial. Potential procedures include cardiac ablation and left atrial appendage closure among others. Greater than 400,000 patients per year in the United States may benefit – with procedures ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you